Is Novartis's ground-breaking Alzheimer's prevention study over-ambitious?
This article was originally published in Scrip
Executive Summary
Novartis is to test two of its investigational anti-amyloid therapies in a novel approach to prevent or delay the onset of Alzheimer's in people at a genetic risk for developing the disease, but some experts are sceptical about the wisdom of the approach.